NCT00528047View on ClinicalTrials.gov

Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

March 31, 2011

Study Completion Date

November 30, 2011

Conditions
Cancer
Interventions
DRUG

PRLX 93936

PRLX 93936 will be administered intravenously over one hour daily for 5 days.

Trial Locations (3)

85258

TGen Clinical Research Services at Scottsdale Healthcare, Scottsdale

90211

Tower Cancer Research Foundation, Beverly Hills

02115

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
lead

Prolexys Pharmaceuticals

INDUSTRY